Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 10/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.46 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8970796 | 1.00 | SIGMAR1 (0.50) | SIGMAR1OPRM1SLC6A3ACHEKCNH2 | |
| SCHEMBL8970828 | 0.81 | SIGMAR1 (0.56) | SIGMAR1OPRM1SLC6A3ACHEKCNH2 | |
| SCHEMBL8970769 | 0.76 | SLC6A3 (0.56) | SIGMAR1OPRM1SLC6A3ACHE | |
| SCHEMBL3566447 | 0.75 | SLC6A3 (0.54) | SIGMAR1OPRM1SLC6A3ACHEKCNH2 | |
| SCHEMBL8970787 | 0.73 | SLC6A3 (0.56) | SIGMAR1OPRM1SLC6A3ACHE | |
| SCHEMBL15470506 | 0.73 | SLC6A3 (0.51) | SIGMAR1OPRM1SLC6A3 | |
| SCHEMBL422176 | 0.72 | SIGMAR1 (0.76) | SIGMAR1SLC6A3ACHEKCNH2 | |
| SCHEMBL21726765 | 0.72 | SLC6A3 (0.59) | SIGMAR1SLC6A3ACHE | |
| SCHEMBL6056974 | 0.72 | SLC6A3 (0.83) | SIGMAR1SLC6A3ACHEKCNH2 | |
| SCHEMBL14407778 | 0.72 | SLC6A3 (0.83) | SIGMAR1SLC6A3ACHEKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5480892-A | SIGMA RECEPTOR ANTAGONISTS; TREATMENT OF PHYSIOLOGICAL OR DRUG INDUCED PSYCHOSIS AND DYSKINESIA | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-01-02 | — | — | US | disclosed |
| US-5356906-A | (N-phthalimidoalkyl) piperidines useful as treatments for psychosis | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-10-18 | — | — | US | disclosed |
| WO-1993022310-A1 | (N-PHTHALIMIDOALKYL)PIPERIDINES FOR THE TREATMENT OF PSYCHOSES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-11-11 | — | — | WO | disclosed |
| EP-0497843-A4 | (N-PHTHALIMIDOALKYL) PIPERIDINES | — | 1992-09-23 | — | — | EP | disclosed |
| EP-0497843-A1 | (N-PHTHALIMIDOALKYL) PIPERIDINES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-08-12 | — | — | EP | disclosed |
| WO-1991006297-A1 | (N-PHTHALIMIDOALKYL) PIPERIDINES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1991-05-16 | — | — | WO | disclosed |